The FDA considers products in the isoxazoline class to be safe and effective for dogs and cats but is providing this information so that pet owners and veterinarians can take it into consideration when choosing flea and tick products for their pets. Isoxazoline products have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures in some dogs and cats. Although most dogs and cats haven’t had neurologic adverse reactions, seizures may occur in animals without a prior history. The FDA-approved drugs in this class are Bravecto (fluralaner) tablets for dogs Bravecto (fluralaner) topical solution for cats and dogs Bravecto Plus (fluralaner and moxidectin) topical solution for cats Bravecto 1-month (fluralaner) tablets for dogs Credelio (lotilaner) tablets for dogs and cats Nexgard (afoxolaner) tablets for dogs Nexgard Plus (afoxolaner, moxidectin, and pyrantel) chewable tablets for dogs. Although these products can and have been safely used in the majority of dogs and cats, pet owners should consult with their veterinarian to review their patients’ medical histories and determine whether a product in the isoxazoline class is appropriate for their pet. If your dog or cat experiences any adverse event while using an isoxazoline product, first consult your veterinarian. The FDA continues to monitor adverse drug event reports for these products and encourages pet owners and veterinarians to report adverse drug events.